Join us in Seattle on November 8th for Bloomberg's intelligent automation briefing about transformation in a time of uncertainty. During this special evening event, top business and IT executives will gather to explore ways in which intelligent automation can offset economic

pressures and help organizations thrive by enhancing operational efficiencies and stakeholder

value.

This program is proudly sponsored by IBM. Register at

Bloomberg Live.com slash automation slash radio. Welcome to the Bloomberg Surveillance Podcast, I'm Tom Keene.

Daily, we bring you insight. Welcome to the Bloomberg Surveillance Podcast. I'm Tom Keene.

Daily, we bring you insight from the best in economics, finance, investment, and international relations.

Find Bloomberg Surveillance on Apple Podcasts, SoundCloud, Bloomberg.com, and of course, on the

Bloomberg.

Right now on the virus, a definitive conversation on COVID with Deborah Fuller of the University

of Washington School of Medicine and

Microbiology Professor. I can't say enough about the esteem of their program.

Dr Fuller, I want to go to the idea that we were all afraid of measles and maybe

Xe antevaxers were less afraid of measles now and there's different variance of

measles D4 B2 whatever those numbers are are the variance of this virus to be treated like the

variance of other things we've contained or are the variance here different?

The variance here could be quite different and that's just because we have

increasing evidence that some of these new SARS-Cov2 variants are not only gaining on ability to transmit more efficiently,

but developing mutations that could potentially evade antibody mean responses and that would potentially suggest that our current vaccines

it might impact the efficacy of our current vaccines.

Now our vaccines are very high efficacy. it might impact the efficacy of our current vaccines.

Now, our vaccines are very high efficacy, much higher than 90%.

...